Recurrent Endometrial Carcinoma clinical trials

Explore recruiting recurrent endometrial carcinoma clinical trials.

Recruiting recurrent endometrial carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Recurrent Endometrial Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Netherlands, Greece, Denmark, Poland, Spain, Italy +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

Italy, Spain, Denmark, Finland, Germany, Ireland +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Ireland, Austria, Italy, Spain, Belgium, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Comparative Bioavailability of Lenvatinib 10 mg Capsules: A Two-Part, Single-Dose, Open-Label, Randomized, Six-Sequence, Three-Treatment, Three-Period, Crossover Pilot Study in Healthy Subjects Under Fasting and Fed Conditions.

Portugal

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Recurrent Endometrial Carcinoma trials by city

Recurrent Endometrial Carcinoma clinical trials

Recruiting recurrent endometrial carcinoma studies right now

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Cs-131LDR Brachytherapy for Organ-Preserving Irradiation for Recurrent Cervical and Endometrial Cancer

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Also recruiting in Europe

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Comparative Bioavailability of Lenvatinib 10 mg Capsules: A Two-Part, Single-Dose, Open-Label, Randomized, Six-Sequence, Three-Treatment, Three-Period, Crossover Pilot Study in Healthy Subjects Under Fasting and Fed Conditions.

Recurrent Endometrial Carcinoma trials by city

Other conditions